297 related articles for article (PubMed ID: 34863080)
1. The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism.
Zhu H; Xiao Y; Guo H; Guo Y; Huang Y; Shan Y; Bai Y; Lin X; Lu H
Aging (Albany NY); 2021 Dec; 13(23):25089-25105. PubMed ID: 34863080
[TBL] [Abstract][Full Text] [Related]
2. Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR signaling pathway.
Lin M; Xiao Y; Dai Y; Mao Y; Xu L; Zhang Q; Chen Z
Clin Transl Oncol; 2024 Apr; 26(4):951-965. PubMed ID: 37848695
[TBL] [Abstract][Full Text] [Related]
3. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
Cui J; Guo Y; Wu H; Xiong J; Peng T
Mol Med; 2021 Apr; 27(1):38. PubMed ID: 33849427
[TBL] [Abstract][Full Text] [Related]
4. Puerarin 6″-O-xyloside suppressed HCC via regulating proliferation, stemness, and apoptosis with inhibited PI3K/AKT/mTOR.
Li L; Liu JD; Gao GD; Zhang K; Song YW; Li HB
Cancer Med; 2020 Sep; 9(17):6399-6410. PubMed ID: 32691991
[TBL] [Abstract][Full Text] [Related]
5. Tsoong induces apoptosis and inhibits proliferation, migration and invasion of pancreatic ductal adenocarcinoma cells.
Luan YP; Li QF; Wu SG; Mao DC; Deng YY; Chen RW
Mol Med Rep; 2018 Mar; 17(3):3527-3536. PubMed ID: 29286105
[TBL] [Abstract][Full Text] [Related]
6. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
7. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
[TBL] [Abstract][Full Text] [Related]
8. Quercetin suppresses pancreatic ductal adenocarcinoma progression via inhibition of SHH and TGF-β/Smad signaling pathways.
Guo Y; Tong Y; Zhu H; Xiao Y; Guo H; Shang L; Zheng W; Ma S; Liu X; Bai Y
Cell Biol Toxicol; 2021 Jun; 37(3):479-496. PubMed ID: 33070227
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of laminin-5 gamma-2 promotes tumorigenesis of pancreatic ductal adenocarcinoma through EGFR/ERK1/2/AKT/mTOR cascade.
Kirtonia A; Pandey AK; Ramachandran B; Mishra DP; Dawson DW; Sethi G; Ganesan TS; Koeffler HP; Garg M
Cell Mol Life Sci; 2022 Jun; 79(7):362. PubMed ID: 35699794
[TBL] [Abstract][Full Text] [Related]
10. UCP2 inhibition induces ROS/Akt/mTOR axis: Role of GAPDH nuclear translocation in genipin/everolimus anticancer synergism.
Dando I; Pacchiana R; Pozza ED; Cataldo I; Bruno S; Conti P; Cordani M; Grimaldi A; Butera G; Caraglia M; Scarpa A; Palmieri M; Donadelli M
Free Radic Biol Med; 2017 Dec; 113():176-189. PubMed ID: 28962872
[TBL] [Abstract][Full Text] [Related]
11. Paraoxonase 2 Facilitates Pancreatic Cancer Growth and Metastasis by Stimulating GLUT1-Mediated Glucose Transport.
Nagarajan A; Dogra SK; Sun L; Gandotra N; Ho T; Cai G; Cline G; Kumar P; Cowles RA; Wajapeyee N
Mol Cell; 2017 Aug; 67(4):685-701.e6. PubMed ID: 28803777
[TBL] [Abstract][Full Text] [Related]
12. Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis.
Chen L; Xu X; Wen X; Xu S; Wang L; Lu W; Jiang M; Huang J; Yang D; Wang J; Zheng M; Zhou XZ; Lu KP; Liu H
Cancer Sci; 2019 Aug; 110(8):2442-2455. PubMed ID: 31148345
[TBL] [Abstract][Full Text] [Related]
13. Qingyihuaji Formula promotes apoptosis and autophagy through inhibition of MAPK/ERK and PI3K/Akt/mTOR signaling pathway on pancreatic cancer in vivo and in vitro.
Qian X; Bi QY; Wang ZN; Han F; Liu LM; Song LB; Li CY; Zhang AQ; Ji XM
J Ethnopharmacol; 2023 May; 307():116198. PubMed ID: 36690307
[TBL] [Abstract][Full Text] [Related]
14. The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation.
Guo Y; Xiao Y; Guo H; Zhu H; Chen D; Wang J; Deng J; Lan J; Liu X; Zhang Q; Bai Y
Aging (Albany NY); 2021 Jul; 13(14):18545-18563. PubMed ID: 34320467
[TBL] [Abstract][Full Text] [Related]
15. Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo.
Sano M; Ichimaru Y; Kurita M; Hayashi E; Homma T; Saito H; Masuda S; Nemoto N; Hemmi A; Suzuki T; Miyairi S; Hao H
Cancer Lett; 2017 Jul; 397():72-82. PubMed ID: 28347789
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
Momeny M; Alishahi Z; Eyvani H; Esmaeili F; Zaghal A; Ghaffari P; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2020 Feb; 43(1):81-93. PubMed ID: 31512195
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic tigecycline inhibits cell proliferation, migration and invasion via down-regulating CCNE2 in pancreatic ductal adenocarcinoma.
Yang J; Dong Z; Ren A; Fu G; Zhang K; Li C; Wang X; Cui H
J Cell Mol Med; 2020 Apr; 24(7):4245-4260. PubMed ID: 32141702
[TBL] [Abstract][Full Text] [Related]
18. Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway.
Liu X; Tan X; Liu P; Wu Y; Qian S; Zhang X
Oncol Res; 2018 Aug; 26(7):1123-1131. PubMed ID: 29386088
[TBL] [Abstract][Full Text] [Related]
19. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.
Totiger TM; Srinivasan S; Jala VR; Lamichhane P; Dosch AR; Gaidarski AA; Joshi C; Rangappa S; Castellanos J; Vemula PK; Chen X; Kwon D; Kashikar N; VanSaun M; Merchant NB; Nagathihalli NS
Mol Cancer Ther; 2019 Feb; 18(2):301-311. PubMed ID: 30404927
[TBL] [Abstract][Full Text] [Related]
20. A pharmacogenomic analysis using L1000CDS
Choi EA; Choi YS; Lee EJ; Singh SR; Kim SC; Chang S
Cancer Lett; 2019 Nov; 465():82-93. PubMed ID: 31404615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
